Gubra A/S
The answer first
Does Gubra beat the market?
No, Gubra has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 3% of Nordic stocks
- Quality29
- Value7
- Trend13
No. 184 of 195 in healthcare
Max for seven days
Follow Gubra with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Gubra
Your first answer is free, no account needed.
Do you own Gubra, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Gubra and a few more. Free, no card.
Super Stock+44.6%In short
- Gubra has fallen 39.6% over the past year, including dividends.
- Overall, Gubra ranks better than 3% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 58.1%. The price is 58.1% below its peak now.
Who owns Gubra? See the major shareholders and their stakes
What do analysts think of Gubra?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 3% of Nordic stocks.
No. 184 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 158 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.21
- Asset turnoverSales divided by everything the company owns0.21
- Return on equityProfit divided by equity−17.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 152 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.1
- P/SPrice divided by sales15.7
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 150 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−31.1%
- 6 months−20.6%
- 9 months−28.4%
- 12 months−39.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Gubra
7 funds we follow own Gubra. The share is how much of the fund the stock makes up.
- Norway1
- Sweden2
- Denmark4
- Kvartil Nordiska Småbolag+ Faktor ASweden · Kvartil0.4%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- BIX Danske Aktier Indeks ADenmark · BIX0.1%
- BIX Danske Aktier Indeks Akk ADenmark · BIX0.1%
- Danske Invest Danmark IndeksDenmark · Danske Invest0.1%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
From the funds' latest known holdings.
About Gubra
Gubra A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 330 employees.
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology.


See the full analysis of Gubra.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card